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“...implantable devices can be developed for the simultaneous monitoring of a 
specific group of key metabolites, identified by more complex techniques, such 
as mass spectroscopy- or nuclear magnetic resonance-based analysis.”
Blood analysis is one of the first screening tests 
used to determine the general status of a person. 
From such exams it is possible to determine a 
biochemical analysis of the main metabolites, 
trace molecular profiles of some organs and 
evaluate the cellular state of the blood. Among all 
the important information that can be extracted 
from the compounds present in the bloodstream, 
the identification and monitoring of metabolites 
is a key issue to predict pathological conditions, 
such as ischemia or stroke, or to keep a 
chronic disease under control. Indeed, certain 
metabolites can be up- or down-regulated in 
the blood due to acute or chronic illnesses. A 
complete list of human metabolites has been 
collected in the Human Metabolome Database, 
which counts around 6500 metabolites 
gathered from books, journal articles and 
electronic databases [1]. Metabolomics, which 
is the comprehensive analysis of low-weight 
compounds, is a powerful tool to predict and 
understand several pathologies, such as diabetes, 
obesity, cardiovascular diseases and even cancer, 
by accurately describing the profile of biological 
status [2]. Blood tests are typically carried out 
on a blood sample extracted from the vein 
of the patient in the clinic and subsequently 
analyzed in a laboratory. Mass spectroscopy 
(MS) and nuclear magnetic resonance (NMR) 
are very powerful techniques that offer the 
possibility of metabolomic investigation with 
amazing precision [3]. However, MS and NMR 
are expensive and barely portable techniques. 
Moreover, since blood testing is a ‘discrete’ 
analysis, it is not suitable to follow chronic 
diseases or potentially dangerous conditions 
continuously and it cannot be used to adjust a 
pharmacological treatment.
Implantable devices may genuinely represent 
a valid alternative for continuous monitoring, 
minimizing the pain and the discomfort of the 
person. It is always complicated and sometimes 
dangerous to implant systems that have to be in 
direct contact with the blood. Thrombosis is the 
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main side effect of such implants, which forces 
the patient to receive long-term anticoagulation 
therapies, increasing the risk of bleeding. Since 
there is a strong correlation between metabolite 
concentration in blood and in the extracellular 
space, often it is more convenient to locate 
the implant into the subcutaneous tissues, to 
avoid coagulation problems and long-term 
pharmacological therapies. An outstanding 
example of partial system implantation is the 
GlucoDay® (Menarini Diagnostics) to monitor 
glucose trends over several days [4,5].
In the following section, we describe very recent 
advancements in the field of fully implantable 
devices for the remote monitoring of the human 
metabolism. Indeed, we developed a novel system 
consisting of an implantable and a wearable 
device for the continuous and simultaneous 
monitoring of several metabolites. Then, in the 
‘Future perspective’ we discuss the outstanding 
implications, brought from our solution, for 
clinical practice and therapeutic scopes.
Fully implantable devices
Among all the metabolites listed in the Human 
Metabolome Database, some of them can be 
sensed by existing technologies that are suitable 
to be implanted, such as electrochemical-based 
biosensors. Current disposable point-of-care 
devices are used today, but they do not support 
continuous analysis. Instead, implantable 
devices can be developed for the simultaneous 
monitoring of a specific group of key metabolites, 
identified by more complex techniques, such as 
MS- or NMR-based analysis. They can definitely 
play the role of technologies complementary 
to more general metabolomic techniques, and 
represent the solution for chronic patients.
For this purpose, we designed and realized a 
novel system consisting of an implantable and 
wearable device for the continuous monitoring 
of human metabolism. The implantable portion 
of the device consists of a cylinder 2.2 mm in 
diameter and 15 mm in length to be inserted in 
the interstitial tissues. The device houses several 
electrochemical biosensors for the simultaneous 
monitoring of metabolites and transmits data 
downstream through an information system 
[6]. The platform is then encapsulated in a 
flexible outer casing with an opening that hosts 
a membrane [7]. The membrane allows the 
metabolites to get in touch with the biosensors. 
Experiments in mice have shown low levels 
of toxicity of this implant with the current 
encapsulation. Glucose, lactate, glutamate and 
ATP have been already detected in buffer solution 
as a proof of concept of the device [8–10]. Due 
to the limited size of the implantable device, 
batteries cannot be hosted in the tiny implant. 
The device works in connection with a patch 
(i.e., the wearable device, located on top of the 
skin in the body area where the implant is placed). 
The patch carries out the power transmission, the 
data receiving and the data retransmission onto 
longer distances. The patch communicates also 
via a Bluetooth connection to portable devices, 
such as smartphone, tablet or an external control 
station [11]. The doctor, for example, can remotely 
choose the metabolite to monitor and follow the 
behavior in realtime, through a dedicated interface 
on his/her smartphone or tablet. Otherwise, data 
can be stored in the memory of the phone or 
laptop and analyzed by the expert later.
Future perspective
As mentioned, the system described in the 
previous section was tested for the detection of 
glucose, lactate, glutamate and ATP. Glucose is 
certainly the most widely studied metabolite, 
because it is crucial to the physiology of the 
human body. For a long time, diabetes has driven 
the research and development of devices for 
the monitoring of glucose. However, glycemia 
is also influenced by numerous other factors 
independent from diabetes, like fasting due to 
interventions in the hospital or administration 
of some drugs (i.e., corticosteroids and 
vasopressors). In those cases, the continuous 
monitor ing of glucose levels may alert doctors 
and nursing staff in case the patient is risking 
hypo- or hyper-glycemic conditions [12]. 
Healthy cells contain high intracellular ATP 
concentrations to ensure enough available 
energy currency. Necrosis due to ischemia or 
inf lammation processes causes cell rupture 
and massive ATP release into the extracellular 
matrix. Therefore, ATP monitoring becomes of 
particular interest in chronic inflammation, such 
as inflammatory bowel disease and rheumatoid 
arthritis [13]. The concentration of lactate in 
extracellular fluids is physiologically low, while 
it dramatically increases during hypoxia or 
ischemia and it may create a hostile environment 
for neighboring cells [14]. Glutamate is the 
major excitatory neurotransmitter in the brain 
and is important in synaptic plasticity, axonal 
“Since there is a strong 
correlation between 
metabolite concentration in 
blood and in the 
extracellular space, often it 
is more convenient to 
locate the implant into the 
subcutaneous tissues, to 
avoid coagulation 
problems and long-term 
pharmacological 
therapies.”
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development and neurodegenerative diseases. 
Glutamate dysregulation is often associated 
with multiple psychiatric and cognitive 
disorders [15]. The aforementioned compounds 
are single biomarkers for a specific disease. 
More often, however, it is necessary to monitor 
a group of metabolites in order to get a more 
complete overview of the pathology. Besides the 
straightforward application of an implantable 
sensor for the monitoring of glycemia in diabetic 
people, our recent development has demonstrated 
that it is possible to envisage many other scopes 
for implantable/wearable devices. Perioperative 
sensing of glucose, glutamate, glycerol and 
lactate, for example, may be supportive to 
prevent cerebral metabolic deterioration during 
brain surgery [16]. Glucose, lactate, pyruvate and 
glycerol, however, can be analyzed after liver 
transplantation, in order to avoid graft failure 
and retransplantation [17]. Tumor metabolism 
can also be analyzed by following specific 
biomarkers. Griffiths et al. have shown that the 
mutant tumor has a significant decrease in total 
ATP content with respect to normal tissue [18].
From this perspective, electrochemical 
biosensors offer numerous advantages to be 
applied to implantable devices, including system 
miniaturization and very high versatility. The 
novelties introduced by this experience have 
impacts in both the medical and the engineering 
fields. From the point of view of clinical practice, 
a platform with multiple detection sites may be 
implanted in proximity to the graft to monitor 
the follow-up of the surgery in the early months 
after transplantation. A similar application can 
be exploited in the case of tumor resection. 
Sometimes biomarkers detected in serum may 
not be distinctive enough to evaluate the success 
of a resection. Instead, local biomarker levels can 
often give a better description of the resection 
follow-up. Indeed, short-term detection of cancer 
biomarkers in loco would be useful in revealing 
recurrence of fast growing cells [19]. In the case 
of inflammation, ATP needs to be detected close 
to the inflamed site [20], since the molecule has 
a short half-life and it is quickly converted into 
adenosine [13].
From a more engineering perspective instead, 
the multi-sensor platform was conceived in a 
modular way, which is significantly original 
for this kind of device. In the case of sensors, 
and more generally in the case of new implants, 
the path to commercialization is very long and 
expensive. Devices for glucose monitoring 
are the only exception, where a market exists 
and prospers. Thus, designing sensors for new 
metabolites may incur high non-recurring 
engineering costs, if the manufacturing steps are 
not well planned. However, if sensor micro arrays 
are designed in a modular fashion, similarly 
to what is done in microelectronics, the non-
recurring engineering costs drop significantly. 
Our prototype hosts five areas that can be 
customized to sense different metabolites at a 
later stage, as well as programmable readout 
electronics. Therefore, the notion of the common 
sensing platform helps to reduce development 
costs, time to human trials and manufacturing 
costs because of the higher volume of production, 
eventually resulting in the advance of science, 
technology and medicine.
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“...ATP monitoring 
becomes of particular 
interest in chronic 
inflammation, such as 
inflammatory 
bowel disease and 
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